Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use

Abstract

The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of cocaine use by a cocaine use disorder patient; in preventing relapse into cocaine use by a cocaine use disorder patient; in the promotion of cocaine abstinence by a cocaine use disorder patient; in the treatment of the symptoms of depression or anxiety associated with cocaine use disorder.

Description

[0001] The present invention relates to the use of mGluR5 antagonists. technical field [0002] The present invention relates to an mGluR5 antagonist called mavoglurant or a pharmaceutically acceptable salt thereof, for reducing the use of cocaine by patients with cocaine use disorders; and for preventing cocaine use by patients with cocaine use disorders; Use in promoting cocaine abstinence in patients with cocaine use disorder; use in treating symptoms of depression or anxiety associated with cocaine use disorder. In particular, the present invention relates to the use of Mavogulan or a pharmaceutically acceptable salt thereof in reducing cocaine use by cocaine use disorder patients / preventing cocaine use disorder patients from reusing cocaine. Background technique [0003] Cocaine use disorder is a complex mental disorder defined with reference to DSM-5 criteria (ie, according to the Diagnostic and Statistical Manual of Mental Disorders. 5th Edition, Washington, DC: Ameri...

AI Technical Summary

Problems solved by technology

However, neither MTEP nor MPEP has been further developed due to their shortcomings as therapeutic agents (Keck et al., 2013, Psychopharmacology, 229(2):253-65): for example, MTEP was shown to potently inhibit cytochrome P450 1A2 and rapid metabolism (Smith et al. 2004, Bioorg Med Chem Lett [Bioorganic and Medicinal Chemistry Letters] 14:5481-5484) and, for example, MPEP demonstrated off-target effects on NMDA receptors, monoamine oxidase and norepinephrine transporter (Cosford et al., J.Med.Chem. [Journal of Medicinal Chemistry], 2003, 46(2), pp. 204-206; O'Leary et al., 2000, Br J Pharmacol [British Journal of Pharmacology] 131:1429 -1437; Heidbreder et al., 2003, Synapse 50:269-276; Lea and Faden, 2006 CNS Drug Rev 12:149-166)

Images